SteelPeak Wealth LLC Makes New Investment in Illumina, Inc. $ILMN

SteelPeak Wealth LLC purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) during the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 5,227 shares of the life sciences company’s stock, valued at approximately $644,000.

Several other institutional investors also recently made changes to their positions in ILMN. Elyxium Wealth LLC acquired a new stake in shares of Illumina during the 4th quarter worth $25,000. Creative Capital Management Investments LLC boosted its holdings in Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares during the last quarter. Board of the Pension Protection Fund acquired a new position in Illumina in the fourth quarter valued at $26,000. TD Waterhouse Canada Inc. purchased a new stake in Illumina during the fourth quarter valued at about $26,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in Illumina during the fourth quarter valued at about $26,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ILMN shares. Canaccord Genuity Group upped their price target on Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective on the stock in a research note on Thursday, May 14th. Royal Bank Of Canada assumed coverage on Illumina in a report on Thursday, May 14th. They set an “outperform” rating and a $170.00 target price for the company. Guggenheim increased their target price on shares of Illumina from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Finally, Piper Sandler raised their price target on shares of Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 1st. Nine investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $156.88.

Illumina Stock Down 1.9%

NASDAQ ILMN opened at $186.65 on Friday. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $196.66. The business has a 50 day moving average price of $166.44 and a two-hundred day moving average price of $143.34. The stock has a market cap of $28.24 billion, a PE ratio of 33.94, a P/E/G ratio of 3.49 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the firm posted $0.97 earnings per share. The business’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, sell-side analysts predict that Illumina, Inc. will post 5.22 EPS for the current fiscal year.

Insider Activity

In other news, Director Keith A. Meister sold 235,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the sale, the director directly owned 2,830,452 shares in the company, valued at $463,146,860.76. This trade represents a 7.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Scott D. Ericksen sold 500 shares of Illumina stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $80,000.00. Following the sale, the chief accounting officer owned 14,446 shares in the company, valued at $2,311,360. This represents a 3.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,003,769 shares of company stock valued at $155,710,908 in the last 90 days. Company insiders own 2.90% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.